|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Adalimumab, a fullyhuman anti-tumor necrosis factor alpha monoelonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitantmethotrexate: the ARMADA trial 显示文摘 | Weinblatt ME Keystone EC Furst DE | 2003 | Arthritis Rheum2003，48，： | 1 |
| 2 | Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis 显示文摘 | Michael MH Furst DE Park GS | 2006 | Arthitis Rheum2006，54，2： | 1 |
| 3 | Rheumatoid arthritis pathophysiolo-gy: update on emerging cytokine and cytokine-associat-ed cell targets 显示文摘 | Furst DE Emery P | 2014 | Rheumatology (Oxford)2014，53，9： | 1 |
| 4 | Gout and the risk of a-cute myocardial infarction显示文摘 | Krishnan E Baker JF Furst DE | 2006 | Arthritis Rheum2006，54，8： | 1 |
| 5 | Combination DMARD therapy: rationale and limitations显示文摘 | Furst DE | 1995 | Rheumatol Eur1995，24，： | 1 |
| 6 | Gout and the risk of acute myocardial infarction显示文摘 | Krishnan E Baker JF Furst DE | 2006 | Arthritis Rheum2006，54，8： | 1 |
| 7 | Update consensus statement on biological agents for the treatment of rheumatic disease显示文摘 | Furst DE Keystone EC Kirkham B | 2008 | Ann Rheum Dis2008，67，3： | 1 |
| 8 | Description of the efficacy and safety of three new biologics in the treatment of rheumatoid arthritis显示文摘 | Storage SS Agrawal H Furst DE | 2010 | Korean J Intern Med2010，25，： | 1 |
| 9 | Plasmapheresis for rheumatic diseases in the twenty-first century: take it or leave it?显示文摘 | Bratm-Moscovici Y Furst DE | 2003 | Curr Opin Rheumatol2003，15，3： | 1 |
| 10 | Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases显示文摘 | Breedveld FC Kalden JR | 2003 | Ann Rheum Dis2003，62，： | 1 |
| 11 | 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biolog- ic agents in the treatment of rheumatoid arthritis 显示文摘 | Singh JA Furst DE Bharat A | 2012 | Arthri- tis Care & Research2012，64，5： | 1 |
| 12 | Adalimumab,a fully human anti-tumor necrosis factor-alpha monoclonal antibody,and concomitant standard anti-rheumatic therapy for the treatment of rheumatoid arthritis :results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis )显示文摘 | Schiff MH Fleischmann RM | 2003 | J Rheumatol2003，30，： | 1 |
| 13 | Adalimumab, a fully human anti tumor necrosis factor-α monoclonal antibody, and concomitant standard antirheumatic therpy for the treatment of rheumatoid arthritis: results of STAR ( Safety Trial of Adalimumab in Rheumatoid Arthritis) 显示文摘 | Furst DE Schiff MH Fleischmann RM | 2003 | J Rheumatol2003，30，12： | 1 |
| 14 | Gout and the risk ofacute myocardial infarction显示文摘 | Krishnan E Baker JF Furst DE | 2006 | Arthritis Rheum2006，54，8： | 1 |
| 15 | Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial 显示文摘 | Weinblatt ME Keystone EC Furst DE | 2003 | Arthrtis Rheum2003，48，1： | 1 |
| 16 | Gout and the risk of acute myocardial infarction显示文摘 | Krishnan E Baker JF Furst DE | 2006 | Arthritis Rheum2006，54，8： | 1 |
| 17 | Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept : the opposite study 显示文摘 | Furst DE Gaylis N Bray V | 2007 | Ann Rheum Dis2007，66，： | 1 |
| 18 | Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007 显示文摘 | Furst DE Breedveld FC Kalden JR | 2007 | Ann Rheum Dis2007，66，3： | 1 |
| 19 | Updated consensus statement on biological agents,specifically tumor necrosis factor α (TNFαt) blocking agents and interleukin-1 receptor antagonist(IL-1ra),for the treatment of rheumatic diseases显示文摘 | FURST DE BREEDVELD FC KALDEN JR | 2005 | Ann Rheum Dis2005，，： | 1 |
| 20 | Effect of aspirin and sulindac on methotrexate clearance显示文摘 | Furst DE Herman RA Koehnke R | 1990 | J Pharm Sci1990，79，9： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员